Drug Profile
Odanacatib prodrug - Merck
Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Amides; Biphenyl compounds; Cyclopropanes; Nitriles; Osteoporosis therapies; Small molecules; Sulfones
- Mechanism of Action Bone resorption factor inhibitors; Cathepsin K inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Osteoarthritis in USA (PO)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Osteoarthritis in USA (PO)